6500, rue St-Urbain
Montréal (Québec) H2S 3G9
imagia.com/2019/

Founded in 2015, Imagia is an Artificial Intelligence in Healthcare company, with activities in medical devices and interventional procedures, imaging and diagnostics, personal health and disease management. 

We deliver AI healthcare to our B2B partners, as R&D solutions, digital health products, or fully regulated software-as-medical-devices validated through our ISO13485 MDSAP certified quality system.

Imagia developed EVIDENS, a unique and collaborative, knowledge-based ecosystem that pairs artificial intelligence with clinical expertise to accelerate access to personalized healthcare.

Imagia's initial focus has been on clinical solutions for personalized oncology. We are expanding our research into other therapeutic areas with high burden of disease and significant unmet needs like neurodegenerative diseases.

Imagia is able to address data-related value challenges and is expanding the scope of what is possible by putting clinical experts in the driver seat and enabling them to develop the AI solutions that best address needs. 

Our team is made up of AI and healthcare industry experts, including MDs, with expertise in both AI research and development, and clinical patient management. We also engage with a significant number of international collaborators and interns from countries across the globe.

Participants

Pierre Couture
Director Clinical Collaboration
Pierre.coutureimagia.com
+1 514 247-0564

Shelley Epstein
Vice President, Corporate and Public Affairs
shelleyimagia.com
+1 514 451-6343

2725, chemin Sainte-Foy
Québec (Québec) G1V 4G5
iucpq.qc.ca/en/research/research-centre

The Research Centre of the Quebec Heart and Lung Institute regroups three research components (cardiology, respirology and obesity, type 2 diabetes and metabolism) deemed to be a priority because of the considerable economic and social impact of their related diseases. Our centre’s research themes are central to global health priorities and a major strategic force for halting the progress of non-communicable chronic diseases and their devastating effects. Our centre is unique because our research components perfectly complement the Institute’s clinical missions. This enables health professionals and researchers to work in total synergy to the greatest benefit of patients. This synergy turns research findings into better care. Our research teams harness this synergy for the integrated study of the metabolic triggers of cardiovascular and lung diseases, as well as to develop innovative and competitive Quebec research in disease prevention and treatment.

Participant

Denis Richard
Director of Research
denis.richardcriucpq.ulaval.ca
+1 418-656-8711

2950, chemin de Polytechnique
Montréal (Québec) H3T 1J4
Iricor.ca

IRICoR, a Centre of excellence in commercialization and research specialized in drug discovery, is based at founding University of Montreal’s Institute for Research in Immunology and Cancer (IRIC). IRICoR’s pancanadian mandate is to accelerate the discovery, development, and commercialization of novel therapies in cancer, rare diseases, and related fields. Since 2008, IRICoR has been successfully investing in and supporting selected cutting-edge projects in order to rapidly translate early-stage innovation into potential innovative therapies, through either co-development partnerships with the biopharmaceutical industry or the creation of spin-off companies. IRICoR seamlessly integrates its business-related expertise with access to industry-level drug discovery capabilities, providing selected academic and industry projects with access to its network of experts and cutting-edge infrastructure, including one of the largest academia-based medicinal chemistry groups in Canada.

Participant

Nadine Beauger
Chief Executive Officer
Nadine.beaugeriricor.ca
+1 514 343-6111, ext. 0315
+1 514 293-0430

1075, chemin Ste-Foy
Québec (Québec) G1S 2M1
www.msss.gouv.qc.ca

The mission of the Ministry of Health and Social Services (MSSS) is to maintain, improve and restore the health and well-being of the Québec population by making accessible a set of integrated health and social services services, and quality, thus contributing to the social and economic development of Québec.

According to its mission, the MSSS’s primary role is to ensure the smooth running of Québec’s health and social services system. With a view to improving the health and well-being of the population.

Participant

Sylvie Vézina
Deputy Director General, Information, Performance and Evaluation
Sylvie.vezinamsss.gouv.qc.ca
+1 418 266-8399
+1 418 717-0906

7171, rue Frederick-Banting
Montréal (Québec) H4S 1Z9
Neomed.ca/en/

A foundation of adMare BioInnovations is the NÉOMED Innovation Centre, a vibrant drug discovery hub hosting contract research organizations, biotech companies, and specialized commercialization support services and infrastructure at its state-of-the-art Montréal facilities – a dynamic business ecosystem that is stimulating collaboration and innovation, and amplifying the global competitiveness of Québec life science companies.

NEOMED is now implementing a new innovation and commercialization complex specializing in LSHT, which includes a new 50,000 square feet building. Currently in construction the building will allow NEOMED to bridge a gap in the commercialization of products stemming from university research, in addition to meeting the high demand of SMEs for coaching services, labs, offices and collaborative spaces. The new space is scheduled to be available in July 2020.

Participant

Pierre-Yves Desbiens
Chief of Operations
Pydesbiensneomed.ca
+1 514 865-6093

1405, boulevard du Parc-Technologique
Québec (Québec) G1P 4P5
sovar.com/en/

SOVAR is an innovation powerhouse with mission is to generate economic and social growth by accelerating the emergence, development and deployment of responsible technological and social innovations stemming from cutting-edge research.

In particular, our mandate aims to transfer in our society our most promising and solutions-driven academic partners’ inventions and expertise, in order to improve the world in which we live.

Participant

Paule De Blois
Présidente-directrice générale
CEO
pdebloissovar.com
+1 418 650-2829, ext. 226
+1 418 575-8411

3001, 12^e avenue Nord
Sherbrooke (Québec) J1H 5N4
usherbrooke.ca/medecine

The Sherbrooke University Faculty of Medicine and Health Sciences, founded in 1966, is part of a biomedical complex integrating a university hospital on the Sherbrooke Health Campus. Throughout its growth and expansion, it has maintained a high degree of agility and flexibility that facilitate innovation and research partnerships. Today, it offers over 100 study programs on four in Canada (Sherbrooke, Longueuil, Saguenay and Moncton). Over 200 research professors, several hundred highly qualified professionals and technicians, and another 500 graduate students and postdoctoral fellows carry out leading-edge research. The most recent strategic orientations of research at the Faculty aim to develop Digital Health and Omics for precision health.

Participant

Éric Marsault
Professor
Eric.marsaultusherbrooke.ca
+1 819 821-8000, ext. 72433
+1 819 434-3778

Pavillon James de l’administration
845, rue Sherbrooke Ouest
Montréal (Québec) H3A 0G4
mcgill.ca/research/innovation

Founded in Montreal, Quebec, in 1821, McGill is a leading Canadian post-secondary institution. It has two campuses, 11 faculties, 11 professional schools, 300 programs of study and some 38,000 students, including 8,800 graduate students. McGill attracts students from over 150 countries around the world, with more than 7,700 international students making up 20 per cent of the student body. Almost half of McGill students claim a first language other than English, including 38 per cent who claim French as their first language.

Participant

Olivia Novac
Associate Director, Technology Transfer
Olivia.novacmcgill.ca
+1 514 398-5887
+1 514 830-7884